A monthly PCSK9 shot cut LDL about 56% on top of statins
In the phase 3 LIBerate-HR trial, lerodalcibep lowered LDL cholesterol 56.2% more than placebo at 52 weeks on top of statins. It won approval in 2026; no outcome trial has yet reported.
Do oats really lower cholesterol? The trials say yes — by a real but modest amount
Pooling 58 randomised trials, about 3.5g a day of oat beta-glucan lowered LDL cholesterol by 0.19 mmol/L. A separate meta-analysis of 28 trials found 0.25 mmol/L. Small per person, but consistent.
The Portfolio diet: a plant-based pattern built to lower cholesterol
A randomised trial found the Portfolio diet cut LDL cholesterol by about 13%, and a large cohort study links closer adherence to lower cardiovascular risk. Its authors' industry funding belongs in the record.
Blinded trials do not support most side effects listed on statin labels
An individual-participant meta-analysis of 123,940 people in 19 double-blind trials tested 66 label-listed harms. Four survived correction — none of them the ones patients hear about most.
One infusion of a CRISPR therapy cut ANGPTL3 levels by about 80% in 15 people
The first phase 1 results for CTX310 show gene editing can switch off a lipid gene in the liver. The trial was designed to look for harm, not benefit, and one participant died suddenly.